Amgen
AMGN
$344.72
+2.11%
Amgen Inc. is a leading biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics across a range of serious diseases, operating within the Drug Manufacturers - General industry. The company is a long-established market leader with a diversified portfolio spanning oncology, inflammation, bone health, cardiovascular, and rare diseases, recently bolstered by its acquisition of Horizon Therapeutics. The current investor narrative is dominated by significant regulatory and competitive headwinds, including a recent FDA warning about fatal liver risks associated with its rare disease drug Tavneos and the broader sectoral threat of potential 100% tariffs on drug imports for companies without pricing deals, creating a volatile backdrop for its growth trajectory.…
AMGN
Amgen
$344.72
Related headlines
Investment Opinion: Should I buy AMGN Today?
Rating & Thesis: Hold. Amgen is a financially strong company with a valuable pipeline and cash flow profile, but it is currently navigating significant, binary external risks that cloud the near-term outlook and justify a cautious stance, aligning with the mixed analyst sentiment and a recent downgrade from Buy to Hold.
Supporting Evidence: The valuation appears reasonable, with a forward PE of 14.38x implying strong earnings growth from the estimated EPS of $27.49. Revenue growth remains positive at 8.91% YoY in Q4 2025, and profitability is robust with a TTM net margin of 20.99%. The company's stellar free cash flow generation of $8.1 billion TTM supports its dividend (2.9% yield) and debt service. The implied upside to the analyst-derived price target of ~$395 is a compelling +17%, but this is counterbalanced by the high debt-to-equity ratio of 6.31 and the stock's recent underperformance versus the market.
Risks & Conditions: The two biggest risks that could invalidate a more bullish thesis are a material commercial impact from the Tavneos FDA warning and the imposition of costly import tariffs. This Hold rating would upgrade to a Buy if the Tavneos issue is resolved without major commercial damage and clarity emerges that Amgen will avoid the worst of the tariff policy, likely accompanied by a sustained breakout above the $391 resistance. It would downgrade to a Sell if QoQ earnings volatility worsens, revenue growth decelerates below 5%, or the stock breaks below key support at $267. Based on its forward multiple and growth profile relative to its significant risks, the stock is currently fairly valued, not offering a clear margin of safety nor being egregiously overpriced.
Sign up to view all
AMGN 12-Month Price Forecast
Amgen presents a classic 'GARP with baggage' scenario. Its fundamentals—high cash flow, reasonable forward valuation, and defensive beta—are attractive for a long-term investor. However, the near-term path is obstructed by specific, high-stakes regulatory and policy risks that are difficult to quantify. The base case of modest upside to analyst targets is most probable, but the wide target range reflects high uncertainty. The stance would turn bullish on confirmation of tariff exemption and Tavneos resolution, or bearish on a breakdown below the $267 support level. Investors must be prepared for volatility as these binary events unfold.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $448.14 and implied upside of +30.0% versus the current price.
Average Target
$448.14
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$276 - $448
Analyst target range
Analyst coverage for Amgen is substantial, with 13 analysts providing estimates. The consensus sentiment appears mixed, as institutional ratings show a blend of Buy, Hold/Neutral/Equal Weight, and Overweight actions, with no recent Sell ratings noted. The average target price must be derived from estimated metrics; using the estimated EPS average of $27.49 and the forward PE of 14.38x implies a consensus price target of approximately $395.20, which would represent a +17.1% upside from the current price of $337.6, indicating a bullish lean. The target range is wide, with estimated EPS spanning from a low of $26.50 to a high of $28.82, translating to price targets from roughly $381 to $414 using the forward multiple. The high target likely assumes successful pipeline execution, margin expansion, and no major tariff impacts, while the low target may price in regulatory setbacks for key drugs like Tavneos, competitive pressures, and sustained high debt costs. The recent pattern of analyst actions shows mostly reiterations, with one downgrade from Buy to Hold in February 2026, suggesting a cautious but not panicked stance amid recent news.
Bulls vs Bears: AMGN Investment Factors
The investment debate for Amgen centers on a clash between its strong fundamental engine—robust cash flow, high margins, and a forward valuation pricing in significant earnings growth—against a wall of near-term external risks, including severe regulatory scrutiny on Tavneos and potential tariff headwinds. Currently, the bear case has stronger immediate evidence, as these specific, high-impact risks are actively unfolding and have contributed to the stock's recent underperformance and technical consolidation. The single most important tension is the resolution of the Tavneos safety issue and the company's status regarding drug import tariffs; a favorable outcome on both fronts would likely catalyze a re-rating towards analyst targets, while adverse developments could trigger a re-test of the 52-week low.
Bullish
- Strong Forward Earnings Growth: The forward PE of 14.38x is significantly lower than the trailing PE of 22.84x, implying a 37% earnings growth expectation. This is supported by analyst consensus EPS estimates averaging $27.49, which, when applied to the forward multiple, suggests a price target of ~$395, offering 17% upside from the current price.
- Robust Cash Generation & Financial Health: The company generates substantial free cash flow, with a TTM figure of $8.1 billion. This strong cash flow, coupled with a current ratio of 1.14, provides ample liquidity to service its significant debt from the Horizon acquisition and fund future growth initiatives.
- Diversified Portfolio with New Growth Drivers: Recent launches like Tezspire ($474M) and Tepezza ($457M) are contributing to growth, helping offset mature products. Q4 2025 revenue grew 8.91% YoY to $9.896B, demonstrating the portfolio's ability to deliver positive top-line expansion.
- Defensive Profile with Low Volatility: A beta of 0.416 indicates the stock is significantly less volatile than the broader market, behaving as a defensive holding. This characteristic is attractive in uncertain markets, as evidenced by its 1-year gain of 16.56% despite lagging the SPY's 24.99% return.
Bearish
- Significant Regulatory & Safety Headwinds: Recent FDA warnings about fatal liver risks linked to Tavneos and global scrutiny for data manipulation pose a direct threat to a key rare disease drug. This introduces significant commercial and reputational risk that could impact future revenue streams from this asset.
- Elevated Debt Burden Post-Acquisition: The debt-to-equity ratio of 6.31 is extremely high, reflecting the debt-funded Horizon Therapeutics acquisition. This leverage increases financial risk, exposes the company to higher interest expenses ($653M in Q4 2025), and could constrain financial flexibility.
- Macro & Policy Risk from Potential Tariffs: The threat of 100% tariffs on drug imports for companies without pricing deals creates a stark competitive divide. If Amgen is classified as a holdout, it could face severe cost inflation and competitive disadvantages, directly pressuring margins.
- Technical Weakness & Relative Underperformance: The stock shows negative relative strength versus the SPY over the past 3 months (-18.07%) and 1 year (-8.43%). It is currently trading in the middle of its 52-week range ($267.83 to $391.29), indicating a lack of decisive bullish momentum and consolidation amid negative news flow.
AMGN Technical Analysis
The stock is in a volatile, range-bound consolidation phase after a significant rally earlier in the period. The 1-year price change of +16.56% indicates a positive longer-term trend, but the current price of $337.6 sits approximately 57% of the way from its 52-week low of $267.83 toward its high of $391.29, suggesting it is in the middle of its annual range and lacking decisive directional momentum. Recent momentum shows a stark divergence: the stock is up 2.07% over the past month but down 2.93% over the past three months, indicating that a short-term bounce has not yet reversed a more pronounced medium-term pullback from the February highs near $388. This deceleration from the 1-year trend suggests the stock is digesting its earlier gains amid fundamental news flow. Key technical support is anchored at the 52-week low of $267.83, while immediate resistance is at the recent high and 52-week peak near $391.29. A breakout above $391 would signal a resumption of the primary uptrend, while a breakdown below $267 would indicate a major trend reversal. With a beta of 0.416, the stock exhibits significantly lower volatility than the broader market (SPY), behaving more defensively, which is typical for a large-cap biopharma but also implies it may lag in strong bull markets.
Beta
0.42
0.42x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$268-$391
Price range past year
Annual Return
+19.1%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | +1.6% | -0.2% |
| 3m | -1.1% | +14.0% |
| 6m | +3.2% | +7.8% |
| 1y | +19.1% | +25.3% |
| ytd | +5.2% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Revenue growth has been positive but uneven, with the most recent Q4 2025 revenue of $9.896 billion representing a solid 8.91% year-over-year increase. However, examining the quarterly sequence from Q1 2025 ($8.149B) to Q4 2025 ($9.896B) shows a generally rising trajectory, though growth decelerated from the high double-digit pace seen in earlier 2025 comparisons. Segment data highlights key growth drivers like Prolia ($1.054B), Otezla ($625M), and newer launches Tezspire ($474M) and Tepezza ($457M), offsetting mature products like Enbrel ($532M). The company is profitable, with Q4 2025 net income of $1.333 billion and a robust gross margin of 81.91%. Profitability has been volatile quarter-to-quarter, as seen in the jump from Q3 2025 net income of $3.216 billion (gross margin 67.75%) to the lower Q4 figure, influenced by factors like other expenses; the trailing twelve-month net margin stands at 20.99%. The balance sheet carries significant leverage, with a debt-to-equity ratio of 6.31, reflecting the debt-funded Horizon acquisition. Financial health is supported by strong cash generation, with free cash flow TTM of $8.1 billion and a current ratio of 1.14, providing ample liquidity to service debt and fund operations, though the high debt load remains a key risk factor.
Quarterly Revenue
$9.9B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.81%
Latest Quarter
Free Cash Flow
$8.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. Amgen trades at a trailing PE of 22.84x and a forward PE of 14.38x based on estimated EPS. The substantial gap between trailing and forward multiples implies the market expects a significant earnings recovery or growth, likely factoring in synergies from the Horizon integration and pipeline contributions. Compared to sector averages, data is not available in the provided dataset for a direct industry PE comparison, preventing a quantified premium/discount assessment. Historically, the stock's own trailing PE has fluctuated widely, from lows near 11.36x in early 2023 to highs above 56x in late 2024. The current trailing PE of 22.84x sits below the peak of this range but above the trough, suggesting a moderate valuation that is not excessively stretched relative to its own history, potentially pricing in a stabilization of earnings post-acquisition digestion.
PE
22.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -336x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are dominated by the company's elevated leverage, with a debt-to-equity ratio of 6.31 stemming from the Horizon acquisition. This high debt load results in substantial interest expense, which was $653 million in Q4 2025, pressuring net income. Furthermore, quarterly profitability is volatile, as seen in the sharp drop from Q3 to Q4 2025 net income, driven by fluctuating 'other expenses.' Revenue concentration risk is mitigated by a diversified portfolio, but specific products like Tavneos now face severe regulatory scrutiny, posing a threat to a growth segment.
Market & Competitive Risks are pronounced, with the stock trading at a forward PE of 14.38x, which, while reasonable, offers no margin of safety if growth disappoints. The external threat landscape is severe: the FDA warning on Tavneos introduces commercial and litigation risk, while the potential for 100% tariffs on drug imports for non-compliant companies represents a direct macro-policy threat to cost structure and competitiveness. The stock's low beta of 0.416 suggests defensive characteristics but also implies it may continue to lag in a strong bull market, as evidenced by its significant underperformance versus the SPY over the past year.
Worst-Case Scenario involves a confluence of the Tavneos safety issues leading to severe prescribing restrictions or a label change, combined with Amgen being subject to the proposed 100% import tariffs. This would crush growth expectations for a key drug and significantly increase costs, leading to multiple compression and earnings downgrades. In this adverse scenario, the stock could realistically re-test its 52-week low of $267.83, representing a downside of approximately -21% from the current price of $337.6. A further decline toward the $250 level is plausible if debt concerns amplify during a sector-wide sell-off.
FAQ
The key risks are, in order of severity: 1) Regulatory & Commercial: The FDA warning on fatal liver risks for Tavneos could lead to restricted use and lost sales from a growth drug. 2) Macro-Policy: Potential 100% tariffs on drug imports could drastically increase costs if Amgen is not exempt. 3) Financial: The high debt-to-equity ratio of 6.31 increases interest expense sensitivity and reduces financial flexibility. 4) Competitive & Execution: Volatile quarterly profitability (e.g., Q4 net income of $1.333B vs. Q3's $3.216B) indicates earnings instability that could disappoint the market.
The 12-month forecast is a range of scenarios. The base case (50% probability) targets $381-$395, derived from analyst EPS estimates and the forward PE, implying modest upside. The bull case (30% probability) targets $395-$414, requiring a favorable resolution of the Tavneos and tariff issues. The bear case (20% probability) sees a drop toward the 52-week low of $267, triggered by adverse regulatory actions and tariff imposition. The most likely outcome is the base case, predicated on the company managing, but not fully escaping, its current headwinds while delivering on consensus earnings.
AMGN appears fairly valued relative to its near-term prospects. The forward PE of 14.38x, based on estimated EPS of $27.49, is not excessive for a large-cap biopharma and implies strong earnings growth from the trailing PE of 22.84x. However, this valuation does not provide a clear discount, as it reasonably incorporates both the growth from newer drugs and the risks from high debt (D/E of 6.31) and regulatory headwinds. Compared to its own historical PE range (from ~11x to 56x), the current multiple sits in a moderate zone, suggesting the market is pricing in a stabilization period, not a premium for flawless execution.
AMGN is a moderately good buy for patient, risk-aware investors, but not a compelling one for all. The stock offers a reasonable forward PE of 14.38x, a 2.9% dividend yield, and an implied 17% upside to analyst targets. However, it carries significant near-term risks from the Tavneos FDA warning and potential tariff impacts. It is a good buy for investors who believe these risks are overstated and are seeking a defensive healthcare holding with growth optionality. For those requiring high certainty or explosive growth, it is less suitable.
AMGN is more suitable for a long-term investment horizon of 3-5 years. Its low beta of 0.416 and dividend policy make it a stable holding for building portfolio income and defensive exposure. The near-term is clouded by binary events (tariffs, Tavneos) that could cause significant short-term volatility, making it a challenging trade. Long-term investors can look through this noise to the underlying cash-generating business and pipeline. A minimum holding period of 12-18 months is suggested to allow current uncertainties to resolve and for the Horizon integration benefits to materialize more fully.